Drug discovery could prevent spread of childhood bone cancer
Now, scientists at the University of British Columbia have identified a potential drug that could halt osteosarcoma's spread. In a study...
Sep 18, 2024
FDA Grants Orphan Drug Designation to Opaganib in Neuroblastoma
The FDA has granted a second orphan drug designation to opaganib in oncology, this time for patients with neuroblastoma. Read more:...
Sep 13, 2024
FDA Approves Retevmo for RET-Positive Pediatric Cancers
The Food and Drug Administration (FDA) granted an accelerated approval to Retevmo (selpercatinib) for the children aged two and older...
Jun 6, 2024
Development of novel therapies for pediatric cancer: Successes and challenges
Peter J. Houghton from Greehey Children’s Cancer Research Institute and Mary-Ann Bjornsti from the University of Alabama discuss some of...
Apr 3, 2024
Epigenetic Combination Therapy Could Overcome Treatment Resistance in Epithelioid Sarcomas and Rhabdoid Tumors
Epithelioid sarcoma, a rare aggressive cancer that usually strikes young adults, and rhabdoid tumors, which affect children, have long...
Feb 16, 2024
Experimental Drug May Slow Childhood Brain Tumors
The drug tovorafenib may halt the growth of or shrink some childhood brain tumors, according to a clinical trial published in Nature...
Jan 31, 2024
How research helped lead to FDA approval of a pediatric neuroblastoma drug
The drug, called eflornithine (DFMO) and newly branded as IWILFIN by US WorldMeds, reduces the risk of relapse for pediatric high-risk...
Dec 20, 2023
A well-meaning FDA policy is a threat to pediatric cancer treatment
The medical community today faces a deceptively simple question: How quickly should we act when a child’s life is on the line? I’m a...
Dec 16, 2023
FDA Gives Priority Review to Tovorafenib in Pediatric Low-Grade Glioma
The FDA has granted priority review to a new drug application (NDA) for single-agent tovorafenib (DAY101) as a treatment for those with...
Nov 6, 2023
FDA Expands Rozlytrek Indication to Include Some Solid Tumors in Children at Least 1 Month Old
The Food and Drug Administration (FDA) approved an expanded indication for Rozlytrek (entrectinib) to include children older than one...
Oct 23, 2023